Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01889 (
ankylosing spondylitis
)
5,717
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
With the aim of investigating the role of
suppressor of cytokine signaling 1
(
SOCS1
) in the pathogenesis of systemic lupus erythematosus, 107 patients with systemic lupus erythematosus, 101 healthy controls, and 151 patients with
ankylosing spondylitis
were enrolled in this study.
SOCS1
mRNA level was measured by the method of quantitative real-time polymerase chain reaction.
SOCS1
polymorphisms were detected by the polymerase chain reaction/restriction fragment length polymorphisms method. Systemic lupus erythematosus disease activity was evaluated with the SLEDAI. This study showed that the
SOCS1
mRNA expression was significantly higher in the patients with systemic lupus erythematosus than in the healthy controls (p = 0.0014). Patients with active systemic lupus erythematosus had a higher expression of
SOCS1
mRNA than the patients with inactive systemic lupus erythematosus (p = 0.035). There was no significant difference in the frequencies of the
SOCS1
-1478CA/del polymorphisms among the patients with systemic lupus erythematosus, healthy controls, and patients with
ankylosing spondylitis
. The genotype frequency of the
SOCS1
-1478 polymorphisms in the dominant model (CA/del+del/del versus CA/CA) was significantly decreased in the patients with thrombocytopenia compared with those without thrombocytopenia (p(c) = 0.035). Moreover, the allele frequency of
SOCS1
-1478del was also significantly lower in the patients with thrombocytopenia than in those without thrombocytopenia (p( c) = 0.02). In conclusion, this study demonstrated that the expression of
SOCS1
mRNA was significantly increased in patients with systemic lupus erythematosus. Moreover,
SOCS1
mRNA levels in patients with active systemic lupus erythematosus were significantly higher than those in the inactive patients. We also found that the systemic lupus erythematosus patients with thrombocytopenia have a lower frequency of
SOCS1
-1478del compared with patients without thrombocytopenia.
...
PMID:Suppressor of cytokine signaling 1 gene expression and polymorphisms in systemic lupus erythematosus. 2006 13